Stephens Investment Management Group LLC Lowers Stake in Repligen Co. (NASDAQ:RGEN)

Stephens Investment Management Group LLC lessened its holdings in Repligen Co. (NASDAQ:RGEN) by 2.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 499,744 shares of the biotechnology company’s stock after selling 12,346 shares during the period. Stephens Investment Management Group LLC owned about 0.89% of Repligen worth $74,372,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of RGEN. Toronto Dominion Bank boosted its holdings in Repligen by 1.5% in the 2nd quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company’s stock worth $656,000 after buying an additional 75 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its stake in shares of Repligen by 1.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company’s stock worth $982,000 after acquiring an additional 89 shares during the last quarter. Ballentine Partners LLC increased its position in shares of Repligen by 6.2% during the third quarter. Ballentine Partners LLC now owns 1,807 shares of the biotechnology company’s stock worth $269,000 after purchasing an additional 105 shares in the last quarter. Diversified Trust Co raised its stake in Repligen by 3.7% in the 2nd quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company’s stock valued at $372,000 after purchasing an additional 106 shares during the last quarter. Finally, CWM LLC lifted its holdings in Repligen by 36.3% in the 3rd quarter. CWM LLC now owns 428 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 114 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Stephens reiterated an “overweight” rating and issued a $170.00 target price on shares of Repligen in a research report on Tuesday, July 30th. Benchmark reissued a “hold” rating on shares of Repligen in a research note on Monday, August 5th. Wells Fargo & Company initiated coverage on Repligen in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price target for the company. UBS Group reduced their price objective on Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. Finally, JPMorgan Chase & Co. upped their target price on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Wednesday, July 31st. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $190.25.

Insider Buying and Selling

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the sale, the director now owns 139,840 shares of the company’s stock, valued at $20,328,540.80. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.20% of the stock is currently owned by corporate insiders.

Repligen Stock Performance

Shares of Repligen stock opened at $134.27 on Friday. The business’s fifty day simple moving average is $142.20 and its 200-day simple moving average is $146.15. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26. The firm has a market cap of $7.52 billion, a PE ratio of -3,355.91, a price-to-earnings-growth ratio of 3.92 and a beta of 0.95. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $211.13.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, hitting the consensus estimate of $0.33. The company had revenue of $154.07 million during the quarter, compared to analyst estimates of $154.11 million. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. Repligen’s revenue was down 3.2% compared to the same quarter last year. During the same quarter last year, the firm posted $0.53 earnings per share. Equities analysts forecast that Repligen Co. will post 1.45 earnings per share for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.